相关实验视频
Updated: Jun 15, 2026

10:10
Reverse Total Shoulder Arthroplasty
Published on: July 5, 2011
43.4K
在关节镜旋转手套修复后使用特兰克萨姆酸可减少阿片类药物的使用
Katherine A Burns1, Lynn M Robbins1, Laura Humphrey1
1SSM Health Orthopedics, SSM Health DePaul Hospital, St. Louis, MO, USA.
Journal of shoulder and elbow surgery
|September 4, 2025
概括
在关节镜旋转手套修复 (ARCR) 后,特兰克萨姆酸 (TXA) 显著降低了阿片类药物消耗. 这项研究发现TXA在初始术后期有效降低疼痛药物需求.
科学领域:
- 骨科手术
- 药理学
- 治疗疼痛
背景情况:
- 特兰克萨姆酸 (TXA) 是一种抗纤维溶解剂,已知可减少关节整形手术中流失的血液.
- 之前对TXA在关节镜旋转手套修复 (ARCR) 后对术后疼痛的影响的研究产生了不同的结果.
- 在ARCR后优化疼痛管理和减少阿片类药物依赖是一个重大的临床挑战.
研究的目的:
- 预期评估静脉注射松酸 (TXA) 在关节镜旋转手套修复 (ARCR) 后的前三天对处方阿片类药物的影响.
- 评估TXA对ARCR后主观疼痛评分 (视觉模拟尺度 (VAS)) 的影响.
- 在ARCR后确定影响术后阿片类药物使用的因素.
主要方法:
- 这是一项前性,双盲,随机,安慰剂对照试验,涉及接受ARCR的患者.
- 静脉注射TXA (1000mg) 与静脉注射盐酸安慰剂的比较
- 主要结局:在手术后的前3天内服用阿片类药物 (吗啡毫克相当量).
- 二次结局:视觉模拟度 (VAS) 疼痛评分在术后的前3天.
主要成果:
- 在ARCR后的前3天,TXA显著降低了18MME的阿片类药物消耗量 (p=0. 044).
- 年龄较大与较低的阿片类药物消费有关,而先前使用阿片类药物和更多的使用者显著增加了阿片类药物消费.
- 在TXA和安慰剂组之间没有观察到主观疼痛评分 (VAS) 的显著差异.
结论:
- 静脉注射TXA在关节镜旋转手套修复 (ARCR) 后有效减少阿片类药物消耗.
- 患者的年龄,阿片类药物使用史和手术因素,如的数量影响了术后阿片类药物需求.
- 虽然TXA降低了阿片类药物摄入量,但在ARCR后的早期术后期,它没有显著改变主观疼痛评分.
相关概念视频
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

